All patients who participate in this study will receive pazopanib. Pazopanib is an oral drug
(pill) that has been approved by the U.S. Food and Drug Administration (FDA) for the
treatment of advanced kidney cancer. In this study, the investigators plan to learn more
about the way this drug works by using special scans (MRIs and Ultrasounds) to help evaluate
how this drug is working on this disease. Approximately 20 people with advanced kidney cancer
will be enrolled on this study.
Phase:
Early Phase 1
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania